Asensus Surgical, Inc. Announces Agreement with Flex for Design and Advanced Manufacturing Services for the LUNA™ Surgical System
2023年11月14日 - 6:15AM
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to pioneer a new era of Performance-Guided Surgery™,
today announced an agreement with diversified manufacturer Flex
(NASDAQ: FLEX) for design and advanced manufacturing services for
Asensus’s previously-announced LUNA Surgical System, a
next-generation surgical robot platform.
Flex will provide a range of services across LUNA’s product
lifecycle to enable Asensus Surgical to deliver the platform at
scale, faster. These include design for manufacturing services to
assess and improve LUNA’s manufacturability, ensuring a seamless
and fast transition from product design to ramp to full-scale
manufacturing.
"LUNA is poised to revolutionize the way surgery is performed,
and our top priority is to get the platform to market as quickly
and reliably as possible. Flex’s proven track record of delivering
complex electromechanical systems across diverse industries and
deep understanding of the complex requirements for medical devices
will enable us to accelerate time-to-market for our LUNA platform,”
said Anthony Fernando, Asensus Surgical President and CEO. “Flex’s
focused portfolio of advanced manufacturing capabilities and
trusted supply chain network will also be instrumental in scaling
LUNA globally.”
"The rapid advancement of surgical robotics technology has the
potential to significantly enhance precision and technique in
surgeries, transforming patient care globally,” said Randy Clark,
President, Health Solutions, Flex. “Our collaboration with Asensus
Surgical will enable them to deliver the LUNA platform to market
faster, reliably, and sustainably, making next-generation surgical
robotics solutions more accessible to patients worldwide.”
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the
surgeon and patient to pioneer a new era of Performance-Guided
Surgery by unlocking clinical intelligence for surgeons to enable
consistently superior outcomes and a new standard of surgery. Based
upon the foundations of Digital Laparoscopy and the Senhance®
Surgical System, the Company is developing the LUNA™ Surgical
System, a next generation robotic and instrument system as a
foundation of its Digital Surgery solution. These systems will be
powered by the Intelligent Surgical Unit™ to increase surgeon
control and reduce surgical variability. With the addition of
machine vision, Augmented Intelligence, and deep learning
capabilities throughout the surgical experience, we intend to
holistically address the current clinical, cognitive and economic
shortcomings that drive surgical outcomes and value-based
healthcare. The Senhance Surgical System is now available for sale
in the US, EU, Japan, Russia, and select other countries. For a
complete list of indications for use, visit:
www.senhance.com/indications. To learn more about
Performance-Guided Surgery,™ Digital Laparoscopy with the
Senhance Surgical System and the new LUNA System visit
www.asensus.com.
About Flex Ltd.
Flex (Reg. No. 199002645H) is the manufacturing partner of
choice that helps a diverse customer base design and build products
that improve the world. Through the collective strength of a global
workforce across 30 countries and responsible, sustainable
operations, Flex delivers technology innovation, supply chain, and
manufacturing solutions to diverse industries and end markets.
Follow Asensus
Email Alerts: https://ir.asensus.com/email-alerts
LinkedIn: https://www.linkedin.com/company/asensus-surgical-inc
Twitter: https://twitter.com/AsensusSurgical
YouTube: https://www.youtube.com/@AsensusSurgical
Vimeo: https://vimeo.com/asxc
TikTok: https://www.tiktok.com/@asensus_surgical
Forward-Looking Statements
This press release includes statements relating to Asensus
Surgical, the LUNA Surgical System and our agreement with Flex Ltd.
These statements and other statements regarding our future plans
and goals constitute "forward looking statements'' within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, and are intended to
qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to risks and uncertainties that are often difficult to
predict, are beyond our control and which may cause results to
differ materially from expectations and include whether Flex’s
proven track record of delivering complex electromechanical systems
across diverse industries and deep understanding of the complex
requirements for medical devices will enable Asensus to accelerate
time-to-market for the LUNA platform, whether Flex’s focused
portfolio of advanced manufacturing capabilities and trusted supply
chain network will be instrumental in scaling LUNA globally and
whether the collaboration between Asensus and Flex will help make
innovative surgical robotics solutions more accessible to patients
worldwide. For a discussion of the risks and uncertainties
associated with the Company’s business, please review our filings
with the Securities and Exchange Commission (SEC). You are
cautioned not to place undue reliance on these forward-looking
statements, which are based on our expectations as of the date of
this press release and speak only as of the origination date of
this press release. We undertake no obligation to publicly update
or revise any forward-looking statement, whether as a result of new
information, future events or otherwise.
ASENSUS SURGICAL CONTACT:
InvestorsMark Klausner or Mike Vallie ICR
Westwickeinvest@asensus.com443-213-0499
MediaDan VentrescaMatter
CommunicationsAsensusPR@matternow.com617-874-5488
MediaChristie HaberFlex Marketing and
CommunicationsChristie.Haber@flex.com714-742-5886
Asensus Surgical (AMEX:ASXC)
過去 株価チャート
から 4 2024 まで 5 2024
Asensus Surgical (AMEX:ASXC)
過去 株価チャート
から 5 2023 まで 5 2024